Voyager Therapeutics (NASDAQ:VYGR) Receives “Outperform” Rating from Wedbush

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other brokerages have also commented on VYGR. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Monday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Stock Performance

NASDAQ VYGR traded down $0.19 during mid-day trading on Wednesday, reaching $3.79. 246,306 shares of the stock were exchanged, compared to its average volume of 358,811. The company has a market capitalization of $206.76 million, a P/E ratio of 5.33 and a beta of 0.99. The business’s 50 day moving average is $4.95 and its 200-day moving average is $5.87. Voyager Therapeutics has a 1 year low of $3.59 and a 1 year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same period in the previous year, the company earned $1.25 earnings per share. Equities analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. Erste Asset Management GmbH acquired a new position in Voyager Therapeutics during the third quarter worth $6,192,000. Vestal Point Capital LP raised its holdings in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after acquiring an additional 740,000 shares during the period. Farallon Capital Management LLC boosted its position in shares of Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after acquiring an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Voyager Therapeutics by 24.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after purchasing an additional 275,571 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $746,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.